Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Summary: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are key therapeutic agents in the management of metastatic hormone-receptor-positive breast cancer. However, the emergence of drug resistance limits their long-term efficacy. Here, we show that breast cancer cells develop CDK4/6i resistan...

Full description

Bibliographic Details
Main Authors: Sungsoo Kim, Jessica Armand, Anton Safonov, Mimi Zhang, Rajesh K. Soni, Gary Schwartz, Julia E. McGuinness, Hanina Hibshoosh, Pedram Razavi, Minah Kim, Sarat Chandarlapaty, Hee Won Yang
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Cell Reports
Subjects:
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S221112472301210X

Internet

http://www.sciencedirect.com/science/article/pii/S221112472301210X

Similar Items